Apellis Pharmaceuticals, Inc.
APLSDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Apellis Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Apellis Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wheeler Craig A | Director | 0 | May 14, 2026 | 2 |
| Dolsten Mikael | Director | 0 | May 14, 2026 | 2 |
| Machiels Alec | Director | 0 | May 14, 2026 | 2 |
| Chan Gerald | Director | 0 | May 14, 2026 | 2 |
| Watson David O. | General Counsel | 0 | May 14, 2026 | 9 |
| Deschatelets Pascal | Chief Scientific Officer | 0 | May 14, 2026 | 5 |
| Francois Cedric | Chief Executive Officer | 0 | May 14, 2026 | 7 |
| Sullivan Timothy Eugene | Chief Financial Officer | 0 | May 14, 2026 | 7 |
| O'Brien Stephanie Monaghan | Director | 0 | May 14, 2026 | 3 |
| Dunlop A. Sinclair | Director | 0 | May 14, 2026 | 4 |
| Fonteyne Paul R. | Director | 0 | May 14, 2026 | 2 |
| Nicholson Nur | Chief Technical Officer | 0 | May 14, 2026 | 5 |
| Chopas James George | VP/Chief Accounting Officer | 0 | May 14, 2026 | 5 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | May 14, 2026 | 6 |
| Baumal Caroline | Chief Medical Officer | 0 | May 14, 2026 | 5 |
| Walbert Keli | Director | 0 | May 14, 2026 | 2 |
| Boucher Kelley | Chief People Officer | 0 | May 14, 2026 | 2 |
| Meltzer Leslie | Chief Research and Development | 0 | May 14, 2026 | 2 |
| Townsend Adam J. | Chief Commercial Officer | 84,050 | Jan 30, 2025 | 0 |
| Lewis Karen | Chief People Officer | 70,251 | Jan 30, 2025 | 0 |
| Eisele Jeffrey | Chief Development Officer | 55,312 | Jan 30, 2025 | 0 |
| Scheibler Lukas | Chief Research Officer | 68,299 | Dec 5, 2023 | 0 |
| Brown Victoria L. | Program Team Lead | 23,556 | Jan 24, 2023 | 0 |
| Grossi Federico | Chief Medical Officer | 94,884 | Jan 9, 2023 | 0 |
| Morningside Venture Investments Ltd | 10% Owner | 12,806,342 | Nov 18, 2021 | 0 |
| Perry Nicole D | Vice President - Accounting | 4,847 | Aug 3, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2022 (view filing) | Jun 27 | 2 days | Dunlop A. SinclairDirector | SSale | −1.34K | $46.79 | −$62.7K | −50.0%1.34K after | |
| Jul 12, 2022 (view filing) | Jul 8 | 4 days | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $47.95 | −$575.4K | −1.3%937.8K after | |
| Jul 12, 2022 (view filing) | Jul 11 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $48.42 | −$242.1K | −10.4%42.9K after | |
| Jul 18, 2022 (view filing) | Jul 15 | 3 days | Machiels AlecDirector | SSale | −1.25K | $46.33 | −$57.9K | −0.5%263.8K after | |
| Jul 21, 2022 (view filing) | Jul 19 | 2 days | DeLong Mark JeffreySenior Vice President | SSale | −5.00K | $56.42 | −$282.1K | −14.6%29.3K after | |
| Jul 28, 2022 (view filing) | Jul 27 | 1 day | DeLong Mark JeffreySenior Vice President | SSale | −5.00K | $57.00 | −$285.0K | −14.6%29.3K after | |
| Aug 2, 2022 (view filing) | Aug 1 | 1 day | Grossi FedericoCHIEF MEDICAL OFFICER | SSale | −2.50K | $55.99 | −$140.0K | −2.3%107.4K after | |
| Aug 4, 2022 (view filing) | Aug 3 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $56.43 | −$282.1K | −11.7%37.9K after | |
| Aug 8, 2022 (view filing) | Aug 4 | 4 days | DeLong Mark JeffreySenior Vice President | SSale | −10.0K | $60.75 | −$607.5K | −25.5%29.3K after | 2 lots |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | DeLong Mark JeffreySenior Vice President | SSale | −5.00K | $64.50 | −$322.5K | −14.6%29.3K after | |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $62.50 | −$750.0K | −1.3%944.3K after | |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −12.5K | $65.00 | −$812.5K | −22.6%42.9K after | |
| Aug 12, 2022 (view filing) | Aug 11 | 1 day | Dunlop A. SinclairDirector | SSale | −30.0K | $65.63 | −$1.97M | −10.5%255.7K after | |
| Aug 12, 2022 (view filing) | Aug 11 | 1 day | DeLong Mark JeffreySenior Vice President | SSale | −5.00K | $67.00 | −$335.0K | −14.6%29.3K after | |
| Aug 12, 2022 (view filing) | Aug 11 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −12.5K | $67.00 | −$837.5K | −22.6%42.9K after | |
| Aug 16, 2022 (view filing) | Aug 15 | 1 day | Machiels AlecDirector | SSale | −1.25K | $67.21 | −$84.0K | −0.5%263.8K after | |
| Aug 16, 2022 (view filing) | Aug 15 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −12.5K | $69.00 | −$862.5K | −22.6%42.9K after | |
| Aug 18, 2022 (view filing) | Aug 17 | 1 day | DeLong Mark JeffreySenior Vice President | SSale | −5.00K | $69.50 | −$347.5K | −14.6%29.3K after | |
| Sep 2, 2022 (view filing) | Sep 1 | 1 day | Grossi FedericoCHIEF MEDICAL OFFICER | SSale | −2.50K | $60.30 | −$150.8K | −2.3%104.9K after | |
| Sep 7, 2022 (view filing) | Sep 6 | 1 day | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $60.38 | −$301.9K | −10.4%42.9K after | |
| Sep 8, 2022 (view filing) | Sep 8 | Same day | Dunlop A. SinclairDirector | SSale | −15.0K | $65.00 | −$975.0K | −5.9%240.7K after | |
| Sep 12, 2022 (view filing) | Sep 8 | 4 days | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $63.98 | −$767.8K | −1.2%950.8K after | |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Machiels AlecDirector | SSale | −1.25K | $66.00 | −$82.5K | −0.5%263.8K after | |
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $66.69 | −$333.4K | −10.4%42.9K after | |
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | Grossi FedericoCHIEF MEDICAL OFFICER | SSale | −2.50K | $66.69 | −$166.7K | −2.4%102.4K after | |
| Oct 11, 2022 (view filing) | Oct 10 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $57.50 | −$690.0K | −1.2%957.3K after | |
| Oct 17, 2022 (view filing) | Oct 14 | 3 days | Machiels AlecDirector | SSale | −1.25K | $59.31 | −$74.1K | −0.5%263.8K after | |
| Nov 3, 2022 (view filing) | Nov 1 | 2 days | Grossi FedericoChief Medical Officer | SSale | −2.50K | $60.83 | −$152.1K | −2.4%99.9K after | |
| Nov 3, 2022 (view filing) | Nov 1 | 2 days | Dunlop A. SinclairDirector | SSale | −500 | $60.83 | −$30.4K | −0.4%129.9K after | |
| Nov 7, 2022 (view filing) | Nov 3 | 4 days | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $58.54 | −$292.7K | −10.4%42.9K after | |
| Nov 10, 2022 (view filing) | Nov 8 | 2 days | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $46.47 | −$557.6K | −1.2%963.8K after | |
| Nov 17, 2022 (view filing) | Nov 15 | 2 days | Machiels AlecDirector | SSale | −1.25K | $48.01 | −$60.0K | −0.5%263.8K after | |
| Dec 2, 2022 (view filing) | Dec 1 | 1 day | Grossi FedericoChief Medical Officer | SSale | −2.50K | $49.93 | −$124.8K | −2.5%97.4K after | |
| Dec 2, 2022 (view filing) | Dec 1 | 1 day | Dunlop A. SinclairDirector | SSale | −500 | $49.93 | −$25.0K | −0.4%129.4K after | |
| Dec 7, 2022 (view filing) | Dec 5 | 2 days | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $50.38 | −$251.9K | −10.4%42.9K after | |
| Dec 12, 2022 (view filing) | Dec 8 | 4 days | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $47.50 | −$570.0K | −1.2%970.3K after | |
| Dec 19, 2022 (view filing) | Dec 15 | 4 days | Machiels AlecDirector | SSale | −1.25K | $52.35 | −$65.4K | −0.5%263.8K after | |
| Dec 21, 2022 (view filing) | Dec 19 | 2 days | Francois CedricChief Executive Officer | SSale | −28.2K | $52.06 | −$1.47M | −2.8%965.1K after | 2 lots |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Dunlop A. SinclairDirector | SSale | −500 | $50.70 | −$25.4K | −0.4%132.8K after | |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $50.70 | −$253.5K | −10.4%42.9K after | |
| Jan 9, 2023 (view filing) | Jan 5 | 4 days | Grossi FedericoChief Medical Officer | SSale | −2.50K | $48.79 | −$122.0K | −2.6%94.9K after | |
| Jan 10, 2023 (view filing) | Jan 9 | 1 day | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $46.08 | −$553.0K | −1.2%983.8K after | |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | Machiels AlecDirector | SSale | −1.25K | $52.42 | −$65.5K | −0.5%267.6K after | |
| Jan 25, 2023 (view filing) | Jan 23 | 2 days | Eisele JeffreyChief Development Officer | SSale | −4.48K | $51.58 | −$231.0K | −8.6%47.7K after | |
| Jan 25, 2023 (view filing) | Jan 23 | 2 days | Lewis KarenChief People Officer | SSale | −2.96K | $51.58 | −$152.4K | −7.3%37.7K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Lewis KarenChief People Officer | SSale | −883 | $52.76 | −$46.6K | −2.4%36.5K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Eisele JeffreyChief Development Officer | SSale | −883 | $52.76 | −$46.6K | −1.9%46.5K after | |
| Feb 2, 2023 (view filing) | Feb 1 | 1 day | Dunlop A. SinclairDirector | SSale | −500 | $52.61 | −$26.3K | −0.4%132.3K after | |
| Feb 6, 2023 (view filing) | Feb 3 | 3 days | Townsend Adam J.Chief Commercial Officer | SSale | −5.00K | $55.85 | −$279.3K | −6.9%67.9K after | |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Deschatelets PascalChief Scientific Officer | SSale | −12.0K | $54.45 | −$653.4K | −1.2%1.01M after |